JP2017506267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506267A5 JP2017506267A5 JP2016570919A JP2016570919A JP2017506267A5 JP 2017506267 A5 JP2017506267 A5 JP 2017506267A5 JP 2016570919 A JP2016570919 A JP 2016570919A JP 2016570919 A JP2016570919 A JP 2016570919A JP 2017506267 A5 JP2017506267 A5 JP 2017506267A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- compound
- cancer
- salt according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 ethoxyl Chemical group 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 229910052786 argon Inorganic materials 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 36
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000006414 CCl Chemical group ClC* 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000010505 Nose Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000037432 Thymic tumor Diseases 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 1
- 150000002366 halogen compounds Chemical class 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000037830 nasal cancer Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 208000037968 sinus cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000009377 thymus cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000037965 uterine sarcoma Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- YZKFMBAOEVINLP-UHFFFAOYSA-N 4-[2-(3-bromophenoxy)ethyl]morpholine Chemical compound BrC1=CC=CC(OCCN2CCOCC2)=C1 YZKFMBAOEVINLP-UHFFFAOYSA-N 0.000 description 1
- ZEBIFELTRAVDRY-UHFFFAOYSA-N 5-[3-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound N1(CCOCC1)CCOC=1C=C(C=CC=1)C=1C=CC(=NC=1)N ZEBIFELTRAVDRY-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- COAWUHFFAGZMLK-UHFFFAOYSA-N N-[5-[3-(cyclopropylamino)-5-(4-methylpiperazin-1-yl)phenyl]-6-methylpyridin-2-yl]-2-methylpyrimidine-5-carboxamide Chemical compound C1(CC1)NC=1C=C(C=C(C=1)N1CCN(CC1)C)C=1C=CC(=NC=1C)NC(=O)C=1C=NC(=NC=1)C COAWUHFFAGZMLK-UHFFFAOYSA-N 0.000 description 1
- OACMAACLKLQFMP-UHFFFAOYSA-N N-[5-[3-chloro-5-(4-methylpiperazin-1-yl)phenyl]-6-methylpyridin-2-yl]-2-methylpyrimidine-5-carboxamide Chemical compound ClC=1C=C(C=C(C1)N1CCN(CC1)C)C=1C=CC(=NC1C)NC(=O)C=1C=NC(=NC1)C OACMAACLKLQFMP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461942956P | 2014-02-21 | 2014-02-21 | |
| US61/942,956 | 2014-02-21 | ||
| PCT/US2015/016928 WO2015127284A2 (en) | 2014-02-21 | 2015-02-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506267A JP2017506267A (ja) | 2017-03-02 |
| JP2017506267A5 true JP2017506267A5 (enExample) | 2018-04-05 |
| JP6506313B2 JP6506313B2 (ja) | 2019-04-24 |
Family
ID=52684675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570919A Active JP6506313B2 (ja) | 2014-02-21 | 2015-02-20 | 癌及び増殖性疾患の治療のための抗有糸分裂性アミド |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10016398B2 (enExample) |
| EP (1) | EP3107909B1 (enExample) |
| JP (1) | JP6506313B2 (enExample) |
| KR (1) | KR102420508B1 (enExample) |
| CN (2) | CN114634483B (enExample) |
| AU (1) | AU2015218775C1 (enExample) |
| BR (1) | BR112016019161B1 (enExample) |
| CA (1) | CA2940237C (enExample) |
| ES (1) | ES2893374T3 (enExample) |
| IL (1) | IL247293B (enExample) |
| MX (1) | MX390530B (enExample) |
| RU (1) | RU2713179C2 (enExample) |
| SG (2) | SG10202000590SA (enExample) |
| WO (1) | WO2015127284A2 (enExample) |
| ZA (1) | ZA201606471B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| WO2015127284A2 (en) * | 2014-02-21 | 2015-08-27 | Frost Biologic, Inc. | Antimitotic amides for the treatment of cancer and proliferative disorders |
| CN106727583A (zh) * | 2016-12-12 | 2017-05-31 | 范旭升 | 一种治疗舒张性心衰的药物组合物 |
| US11377436B2 (en) * | 2017-07-12 | 2022-07-05 | The Brigham And Women's Hospital, Inc. | EAAT2 enhancing molecules |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| KR20250173438A (ko) * | 2024-05-30 | 2025-12-10 | 삼진제약주식회사 | Nr2f6 억제제 및 이의 용도 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| JP2003535860A (ja) * | 2000-06-05 | 2003-12-02 | ドン・ア・ファーム・カンパニー・リミテッド | 新規なオキサゾリジノン誘導体及びその製造方法 |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| EP1763348A1 (en) * | 2004-06-30 | 2007-03-21 | Novartis AG | Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors |
| JPWO2007018319A1 (ja) * | 2005-08-11 | 2009-02-19 | 武田薬品工業株式会社 | ピリジルフェノール化合物およびその用途 |
| JP5430944B2 (ja) * | 2006-01-31 | 2014-03-05 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のためのピリジルフェニル化合物 |
| WO2008059042A1 (en) | 2006-11-17 | 2008-05-22 | Smithkline Beecham Corporation | 2-carboxy thiophene derivatives as anti viral agents |
| CA2683624A1 (en) * | 2007-04-12 | 2008-10-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| US20110118281A9 (en) * | 2008-10-01 | 2011-05-19 | Gary Bohnert | Compounds for inflammation and immune-related uses |
| WO2010100475A1 (en) * | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| NZ598758A (en) * | 2009-09-11 | 2013-12-20 | Amgen Inc | N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
| WO2011139489A2 (en) | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| US20130063385A1 (en) * | 2010-05-14 | 2013-03-14 | Sharp Kabushiki Kaisha | Portable information terminal and method for controlling same |
| TWI541243B (zh) * | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| CN103380117A (zh) * | 2011-01-21 | 2013-10-30 | Abbvie公司 | 激酶的吡啶酰胺抑制剂 |
| CN103402985A (zh) * | 2011-02-10 | 2013-11-20 | 先正达参股股份有限公司 | 杀微生物的吡唑衍生物 |
| CN103702665B (zh) * | 2011-05-03 | 2016-08-17 | 幸讬制药公司 | 用于炎症和免疫相关用途的化合物 |
| WO2013063385A1 (en) * | 2011-10-28 | 2013-05-02 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2015127284A2 (en) * | 2014-02-21 | 2015-08-27 | Frost Biologic, Inc. | Antimitotic amides for the treatment of cancer and proliferative disorders |
-
2015
- 2015-02-20 WO PCT/US2015/016928 patent/WO2015127284A2/en not_active Ceased
- 2015-02-20 ES ES15710328T patent/ES2893374T3/es active Active
- 2015-02-20 KR KR1020167026016A patent/KR102420508B1/ko active Active
- 2015-02-20 US US15/120,470 patent/US10016398B2/en active Active
- 2015-02-20 CN CN202210190090.XA patent/CN114634483B/zh active Active
- 2015-02-20 AU AU2015218775A patent/AU2015218775C1/en active Active
- 2015-02-20 JP JP2016570919A patent/JP6506313B2/ja active Active
- 2015-02-20 RU RU2016135555A patent/RU2713179C2/ru active
- 2015-02-20 SG SG10202000590SA patent/SG10202000590SA/en unknown
- 2015-02-20 SG SG11201606869TA patent/SG11201606869TA/en unknown
- 2015-02-20 CA CA2940237A patent/CA2940237C/en active Active
- 2015-02-20 EP EP15710328.4A patent/EP3107909B1/en active Active
- 2015-02-20 BR BR112016019161-7A patent/BR112016019161B1/pt active IP Right Grant
- 2015-02-20 CN CN201580009889.2A patent/CN106068263A/zh active Pending
- 2015-02-20 MX MX2016010877A patent/MX390530B/es unknown
-
2016
- 2016-08-16 IL IL247293A patent/IL247293B/en active IP Right Grant
- 2016-09-20 ZA ZA2016/06471A patent/ZA201606471B/en unknown
-
2018
- 2018-06-29 US US16/024,407 patent/US10772872B2/en active Active
-
2020
- 2020-09-03 US US17/011,589 patent/US11129813B2/en active Active
-
2021
- 2021-09-13 US US17/473,364 patent/US12383533B2/en active Active
-
2025
- 2025-08-12 US US19/297,804 patent/US20260034101A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506267A5 (enExample) | ||
| CN114430741A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP7085032B2 (ja) | ナフチリジン化合物、薬物組成物およびそれらの応用 | |
| CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
| CN103497177B (zh) | 作为c‑Met抑制剂的氨基芳香杂环类化合物及其制备方法 | |
| JP2017504576A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| WO2009114994A1 (zh) | 哒嗪酮类化合物在制备抗肿瘤药物中的用途 | |
| CN110582483A (zh) | 含邻氨基杂芳环炔基的化合物及其制备方法和用途 | |
| CN115605479A (zh) | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| KR20190105679A (ko) | 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용 | |
| CN109111426A (zh) | 一类稠合双环杂芳基或芳基化合物，及其用途 | |
| JP2022527892A (ja) | 小分子ｐｄ－１／ｐｄ－ｌ１阻害剤、ｐｄ－ｌ１抗体との医薬組成物及びその使用 | |
| WO2022083657A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| JP2019522681A5 (enExample) | ||
| CN116514728A (zh) | 一种喹唑啉衍生物及其用途 | |
| EA028512B1 (ru) | N-(гетероарил)сульфонамидные производные, которые могут применяться в качестве s100-ингибиторов | |
| CN116924983A (zh) | 一种新型杂环化合物 | |
| CN101265274A (zh) | 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途 | |
| CN106957303A (zh) | 选择性AuroraA激酶抑制活性的喹唑啉衍生物及其制备方法以及应用 | |
| CN111164087B (zh) | 有助于抑制人三叶因子3的化合物 | |
| WO2019005297A1 (en) | BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| CN108570039B (zh) | 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用 | |
| CN108047182A (zh) | 一种西瑞香素衍生物及其应用 |